|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.34 USD | +0.75% |
|
-1.47% | +8.06% |
| Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
| Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
March 27 (Reuters) - The U.S. Food and Drug Administration approved Akebia Therapeutics' drug to treat anemia caused by chronic kidney disease in dialysis patients, the drugmaker said on Wednesday. (Reporting by Pratik Jain, Vaibhav Sadhamta and Mrinmay Dey in Bengaluru; Editing by Subhranshu Sahu)
| 1st Jan change | Capi. | |
|---|---|---|
| +8.06% | 281M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
AKEBIA THERAPEUTICS, INC. 
